ZBD | $40,000,000 | (Jan 23, 2026)
Allocation Strategy | $2,164,392 | (Jan 23, 2026)
Asymmetric Security | $4,200,000 | (Jan 23, 2026)
MitoRx Therapeutics
United Kingdom
- Oxford, Oxfordshire
- 15/12/2023
- Seed
- $4,000,000
MitoRx Therapeutics is a pre-clinical stage rare disease biotech company aiming to become the leading global developer of medicines arresting the progression of degenerative diseases driven by mitochondrial dysfunction, with a focus on neuromuscular disease, metabolic disease and neurodegenerative disease.
- Industry Biotechnology Research
- Website https://www.mitorxtherapeutics.com/
- LinkedIn https://www.linkedin.com/company/mitorx-therapeutics/about/
Related People
Jon ReesFounder
United Kingdom -
Greater Oxford Area
Jon is an entrepreneurial, innovation and investment-focused life sciences PhD & tenacious leader with deep strategic insight. He can draw on a vast personal network within the investment and drug development industries. Jon founded his fourth company, MitoRx Therapeutics, in 2021.
Jon did his post-doc engineering primary metabolism at the University of Oxford, has a PhD in metabolic engineering from the Royal Holloway University of London, a Masters with Distinction from LJMU and a BSc from University of Manchester Institute for Science and Technology. May consider non-executive director positions.
Cubby | $63,000,000 | (Jan 23, 2026)
Cambio | $18,000,000 | (Jan 23, 2026)
Cork Protocol | $5,500,000 | (Jan 23, 2026)
Yuki | $6,000,000 | (Jan 23, 2026)
Mia Labs | $20,000,000 | (Jan 23, 2026)
Mendra | $82,000,000 | (Jan 23, 2026)
Artie Technologies | $12,000,000 | (Jan 23, 2026)
Antidote Legal | $5,000,000 | (Jan 23, 2026)
One to One Health | $12,000,000 | (Jan 22, 2026)